SIGLEC1 as a novel prognostic factor is regulated by Yiqi Huayu Jiedu Decoction in colorectal cancer.

IF 3.3 3区 医学 Q2 ONCOLOGY Journal of Cancer Pub Date : 2025-01-01 DOI:10.7150/jca.99278
Yejin Zhu, Xinping Wang, Qianyi Wang, Shanfan Shi, Jun He, Chao Jiang
{"title":"<i>SIGLEC1</i> as a novel prognostic factor is regulated by Yiqi Huayu Jiedu Decoction in colorectal cancer.","authors":"Yejin Zhu, Xinping Wang, Qianyi Wang, Shanfan Shi, Jun He, Chao Jiang","doi":"10.7150/jca.99278","DOIUrl":null,"url":null,"abstract":"<p><p>We studied the prognostic value of <i>SIGLEC1</i> in colorectal cancer (CRC) using bioinformatics. <i>SIGLEC1</i> exhibited differential expression between the tumor and control samples, and improved survival was observed in patients with increased <i>SIGLEC1</i> expression. The univariate and multivariate analyses confirmed <i>SIGLEC1</i> as an independent prognostic factor for CRC, based on which a nomogram was constructed for predicting survival in patients with CRC. Additionally, higher <i>SIGLEC1</i> expression was correlated with increased immunological/stromal/ESTIMATE scores as well as immune cell infiltration and was strongly and positively associated with T helper cells and macrophages. Furthermore, significant positive correlations were observed between SIGLEC1 expression and inhibitory/coinhibitory immunological genes. Additionally, the TIDE results of patients with CRC showed that increased <i>SIGLEC1</i> expression was related to poorer immunotherapeutic responses. In clinical samples from patients with CRC, a decrease in <i>SIGLEC1</i> expression was noted compared to para-cancerous tissues and samples from patients who received Yiqi Huayu Jiedu Decoction (YHJD) treatment. The <i>in vivo</i> results indicated the superior efficacy of YHJD against CRC in inhibiting tumor metastasis. Our study demonstrates that SIGLEC1 serves as a prognostic factor for CRC, strongly linked to immune response, and can be modulated by YHJD, suggesting novel avenues for CRC treatment.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 1","pages":"351-367"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660119/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.99278","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We studied the prognostic value of SIGLEC1 in colorectal cancer (CRC) using bioinformatics. SIGLEC1 exhibited differential expression between the tumor and control samples, and improved survival was observed in patients with increased SIGLEC1 expression. The univariate and multivariate analyses confirmed SIGLEC1 as an independent prognostic factor for CRC, based on which a nomogram was constructed for predicting survival in patients with CRC. Additionally, higher SIGLEC1 expression was correlated with increased immunological/stromal/ESTIMATE scores as well as immune cell infiltration and was strongly and positively associated with T helper cells and macrophages. Furthermore, significant positive correlations were observed between SIGLEC1 expression and inhibitory/coinhibitory immunological genes. Additionally, the TIDE results of patients with CRC showed that increased SIGLEC1 expression was related to poorer immunotherapeutic responses. In clinical samples from patients with CRC, a decrease in SIGLEC1 expression was noted compared to para-cancerous tissues and samples from patients who received Yiqi Huayu Jiedu Decoction (YHJD) treatment. The in vivo results indicated the superior efficacy of YHJD against CRC in inhibiting tumor metastasis. Our study demonstrates that SIGLEC1 serves as a prognostic factor for CRC, strongly linked to immune response, and can be modulated by YHJD, suggesting novel avenues for CRC treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
益气化瘀解毒汤调节SIGLEC1作为结直肠癌预后的新因子。
我们利用生物信息学研究了SIGLEC1在结直肠癌(CRC)中的预后价值。SIGLEC1在肿瘤和对照样本中表现出差异表达,并且在SIGLEC1表达增加的患者中观察到生存率的提高。单因素和多因素分析证实了SIGLEC1是CRC的独立预后因素,并在此基础上构建了预测CRC患者生存的nomogram。此外,SIGLEC1的高表达与免疫/基质/ESTIMATE评分增加以及免疫细胞浸润相关,并与T辅助细胞和巨噬细胞密切相关。此外,SIGLEC1的表达与抑制/共抑制免疫基因之间存在显著的正相关。此外,CRC患者的TIDE结果显示,SIGLEC1表达升高与较差的免疫治疗反应有关。在结直肠癌患者的临床样本中,与接受益气化瘀解毒汤治疗的癌旁组织和样本相比,SIGLEC1的表达有所下降。体内实验结果表明,YHJD对结直肠癌具有较好的抑制肿瘤转移的作用。我们的研究表明,SIGLEC1作为结直肠癌的预后因子,与免疫反应密切相关,并可通过YHJD调节,为结直肠癌的治疗提供了新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
Eosin
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
期刊最新文献
ADAM10 is a key player in the diagnosis, prognosis and metastasis of non-small cell lung cancer (NSCLC). Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer. KLK7 Involvement in Thyroid Papillary Carcinoma Cell Migration and Invasion by EMT via MAPK/ERK Pathways. NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells. The Impact of MET Variants in Oral Cancer Progression and Clinicopathological Characteristics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1